A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic...
Atopic DermatitisThe purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Ruxolitinib in Seborrheic Dermatitis
Seborrheic DermatitisThis study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.
Clinical Study of BSZY Cream Intervention to Relieve Atopic Facial Dermatitis
Atopic Dermatitis of Face (Diagnosis)This randomized double-blind controlled trial will be conducted in conducted in the Department of Dermatology at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine in China.An estimated 130 participants will be recruited and randomly assigned to receive BSZY Cream or emulsion matrix group in a l:l ratio using SPSS 25.0 software.Application is twice a day, morning and evening, for four weeks.The primary outcome will be the SCORAD scale.The secondary outcomes included clinical dermatologist assessment forms, patient self-assessment questionnaires, and safety indicators.The adverse events will be recorded for safety evaluation. All data in the study will be analyzed using the SPSS 25.0 statistical software package.
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Adult...
Dermatitis AtopicThis is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD). The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated adult participants with moderate to severe AD. The study duration per participant will be of 180 weeks, including: A screening period of up to 2 to 4 weeks An open label treatment period of up to 160 weeks (approximately 3 years) A post-treatment safety follow-up period of up to 20 weeks after the last dose administration The planned number of visits will be 26 visits.
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
Atopic DermatitisThis single blind study is to primarily evaluate wearable devices and Observer Reported Itch Assessment in children to assess reduction of itch and night-time scratch in response to Crisaborole treatment vs. vehicle treatment (active control comparator without crisaborole) in children with atopic dermatitis (AD). Participants, age 3 months to 11 years with symptomatic mild to moderate AD, along with their primary caregivers will be recruited. The goal of this study is to more fully evaluate the rapid onset of night-time itch and scratch relief, as well as improvements in sleep following treatment with Crisaborole in comparison to vehicle treatment in children with AD. the study will also assess the quality of life (QoL) and sleep within the associated caregivers.
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer...
Breast CancerBreast Cancer Stage4 moreThe purpose of this study is find out whether Oleogel-S10 is an effective treatment for radiation dermatitis when it is used in combination with a standard wound treatment cream called triamcinolone. Oleogel-S10 has shortened the healing time for other types of skin wounds such as burns. Triamcinolone is a cream that is frequently used to treat moderate to severe skin conditions such as skin irritation caused by poison ivy, eczema, sunburn, and rashes.
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With...
Atopic Dermatitis (AD)This is a multinational (China and Korea), multicenter, randomized, double-blind, vehicle-controlled, parallel-group, comparison trial to demonstrate the superiority of 1% OPA-15406 ointment to the vehicle in adult AD subjects.
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
Moderate-to-severe Atopic DermatitisThis is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.
The Study of CM326 in Adult Subjects With Atopic Dermatitis
Atopic DermatitisThis is a open-label, multi-center study to evaluate the safety and efficacy of CM326 in atopic adrmatitis subjects.
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis...
Moderate to Severe Atopic DermatitisThe investigator, the subject, and the sponsor's project team will remain blind throughout the study. Subjects will be randomly assigned to one of the three treatment groups at a ratio of 1:1:1 to be given the drug once a day for 4 weeks.